Colorectal cancer (CRC) is a leading cause of death among men and women in the USA. Encouragingly, the reported death rates from CRC in the USA have dropped by 46%, and screening has had an important ...

Noninvasive surveillance with multitarget stool DNA testing or fecal immunochemical testing (FIT) could potentially match colonoscopy for reducing long-term colorectal cancer (CRC) incidence and ...

Commercial FITs can match NG-MSDT diagnostic results for CRC by lowering the positivity threshold, enhancing sensitivity while maintaining specificity. FITs are accessible, noninvasive CRC screening ...

This is a letter clarifying some points in an article published in the February 2016 issue of AJMC by Berger et al on colorectal cancer screening guidelines. The Cancer Intervention and Surveillance ...

Mayo Clinic researchers conducted a study comparing the efficacy of multitarget stool DNA tests to fecal immunochemical testing for colorectal cancer screening in Alaska Native people. Here are six ...

Results from a new JAMA Network study support the large-scale use of FIT tests. The findings show that those who complete one or more fecal immunochemical test (FIT) screenings are associated with a ...

VANCOUVER, British Columbia -- The novel multitarget stool RNA test (ColoSense) showed high sensitivity for detecting colorectal neoplasia among adults ages 45 and older, according to the phase III ...

Annual fecal immunochemical test-based surveillance could be as effective as colonoscopies in reducing long-term colorectal cancer incidence and mortality, according to a recent study published in ...

Please provide your email address to receive an email when new articles are posted on . Multi-target stool DNA screening tests predicted neoplasia at follow-up colonoscopy more often than fecal ...

Most tuberculosis (TB) testing today relies on sputum samples coughed up from the lungs. This makes intuitive sense since pulmonary (or lung) TB is the most common form of TB and sputum provides ...